Condition: Factor VIII Deficiency, Congenital · Sponsor: Indiana Hemophilia &Thrombosis Center, Inc.
This is a single arm, phase 4, prospective, open-label, United States single-center study to determine the hemostatic characteristics of Hemlibra (emicizumab) as measured by coagulation laboratory parameters in the mild hemophilia A male patient population with endogenous altered FVIII (baseline FVIII activity of \>5% to 30%). The safety and hemostatic efficacy of Hemlibra (emicizumab) in this patient population will be investigated. Secondary outcomes will assess changes in joint health and quality of life in treated patients.
This description comes directly from the study's public registry record.
Amy D Shapiro, MD · 3178710000 · ashapiro@ihtc.org
Usha Sirimalle, MS · 3178710000 · usirimalle@ihtc.org
Always discuss trial participation with your own doctor first.
| Indiana Hemophila @Thrombosis Center | Indianapolis, Indiana, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04567511